Rising demand for noninvasive small-animal imaging techniques anticipated to propel the growth of preclinical imaging market

Preclinical Imaging Market by Type [Modality, Reagents, Software and Services] – Global Outlook & Forecast 2021-2031

According to the deep-dive market assessment study conducted by Growth+ Reports, the global preclinical imaging market was pegged at ~US$ 860 million in 2020. The market is expected to witness a CAGR of ~6.0% from 2021 to 2031. 

Rising demand for noninvasive small-animal imaging techniques, growth opportunities in emerging markets and the launch of technologically advanced products are some of the pivotal factors propelling the growth of the preclinical imaging market. However, high cost of modalities and procedural restrictions on animal testing are likely to restrain the market growth to a certain extent.

Government bodies and numerous organizations across the globe are implementing several initiatives to fast-track the development of preclinical imaging by providing the necessary funding, grants, permissions, clearances & approvals to meet the needs of the healthcare sector. For instance, in Jun 2020, Ireland established first national preclinical imaging centre with an aim to provide enhanced research data to inform new clinical trials and thereby improving patient outcomes. It has been awarded funding of €3.4 million (US$3.8 million) under the Science Foundation Ireland (SFI) Research Infrastructure Programme.

In an effort to maintain their position in the market, prominent players are continuously striving to launch several novel or complementary imaging methods that can offer more advantages. Technological advancements like multi-modal systems that combines the benefits of anatomical modalities such as CT and MR with the functional imaging of PET and SPECT are expected to propel the growth of the market. For instance, in Mar 2020, MR Solutions displayed its latest dry magnet 3T to 9.4T preclinical, multi-modality MRI (with PET or SPECT) and new benchtop PET/CT systems to the imaging science community at the 15th European Molecular Imaging Meeting (EMIM 2020) in Thessaloniki, Greece.

The demand for non-invasive methods for preclinical imaging has increased considerably in the past few years as it allows to conduct the studies without harming the animals or its physiology. It also allows animal to live normal life without being affected by the study, thereby increasing their adoption in preclinical studies.

However, the restrictions placed on animal testing is expected to restrain the growth of the market to a certain extent. For instance, European Union, India, Israel, Sao Paulo, Brazil, South Korea, New Zealand, and Turkey have adopted full or partial animal testing and/or sales restrictions on cosmetics. Whereas, U.K outlawed testing household chemicals (e.g., cleaning and laundry products, air fresheners) on animals.

The Asia Pacific region is projected to be the fastest-growing preclinical imaging market. The high growth of the region can mainly be attributed to its developing healthcare infrastructure and shift of companies focus to the emerging countries owing to low research costs & less-stringent regulatory guidelines. Additionally, increasing government support to pharmaceutical and biotechnology companies for R&D activities is also expected to boost the growth of the market. Countries such as India, China, and Japan in the APAC region, are projected to offer significant growth opportunities owing to flourishing clinical research organizations (CROs) industry in the region.

Some of the prominent players operating in the preclinical imaging market are PerkinElmer Inc., Bruker, FUJIFILM Visualsonics, Inc., Mediso USA, MILabs B.V., MR Solutions, Aspect Imaging, Tri-Modality Imaging, Inc., Miltenyi Biotec, Agilent Technologies, Inc., among others.

awards awards key differentiators

Reach Us


Web –  www.growthplusreports.com